It’s been a tough year for anyone working on the climate agenda. The Trump Administration’s repeal of the endangerment ...

NORTHAMPTON, MA / ACCESS Newswire / March 9, 2026 / Las Vegas SandsAt the end of last year, the Sands corporate office culminated the 2025 Wellness Challenge: Pause and Presence for Team Members, repr ...

Building a company culture that people love participating in starts with listening to employees and acting on their feedback.

Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)─ ...

Last year techUK's Future Visions series explored physical AI as a next-generation technology with cutting-edge uses in robotics, smart machines, and human-machine collaboration. This year, our AI and ...

Grove Collaborative Holdings, Inc. (NYSE:GROV) Q4 2025 Earnings Call Transcript March 5, 2026 Grove Collaborative Holdings, ...

Guest Blog from the Alan Turing Institute on Expanding the UK’s AI Assurance Market in Defence and Security A thriving AI ...

William Douglas has been writing The Color of Hockey blog since 2012. Douglas joined NHL.com in 2019 and writes about people of color in the sport. Today, he profiles Boston Bruins defenseman Jordan ...

Asante Gold Corporation (TSXV: ASE | GSE: ASG | OTCQX: ASGOF) ('Asante” or the 'Company”) a Ghana-focused emerging mid-tier gold producer, is pleased to provide an operational update on the Company’s ...

The FDA assigned a PDUFA target action date of December 22, 2026 - - The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction ...

The study demonstrated a favourable safety profile for DT-9081.

Ifetroban Clinical Progress -- Phase II FIGHT DMD trial showed high-dose treatment improved LVEF by 3.3% versus placebo and 5.4% over propensity-matched controls, with Fast Track, Orphan Drug, and ...